ProShares Ultra Nasdaq Biotechnology (BIB)
| Assets | $291.12M |
| NAV | $103.97 |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 2.80M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Sep 21, 2010 |
| 1-Year Return | - |
| Volume | 9,162 |
| Open | 106.00 |
| Previous Close | 106.99 |
| Day's Range | 104.03 - 105.34 |
| 52-Week Low | 62.45 |
| 52-Week High | 113.06 |
| Beta | 1.95 |
| Holdings | 276 |
| Inception Date | Apr 8, 2010 |
About BIB
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Top 10 Holdings
71.73% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ Biotechnology Index SWAP UBS AG | N/A | 14.96% |
| NASDAQ Biotechnology Index SWAP Citibank NA | N/A | 11.11% |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International | N/A | 11.05% |
| NASDAQ Biotechnology Index SWAP Societe Generale | N/A | 10.85% |
| Net Other Assets / Cash | N/A | 8.09% |
| NASDAQ Biotechnology Index SWAP Bank of America NA | N/A | 4.33% |
| Moderna | MRNA | 3.58% |
| Amgen | AMGN | 2.90% |
| Gilead Sciences | GILD | 2.76% |
| Illumina | ILMN | 2.10% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2021 | $0.00 | Sep 29, 2021 |
| Jun 22, 2021 | $0.00 | Jun 29, 2021 |
| Mar 23, 2021 | $0.00 | Mar 30, 2021 |
| Mar 23, 2016 | $1.0E-6 | Apr 1, 2016 |
News
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
As Covid Cases Mutate, the Biotech Industry Works to Keep Up
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
